Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 22.5.2017 | EN | Official Journal of the European Union | C 161/32 |

---

Action brought on 20 March 2017 — Novartis v EUIPO — Chiesi Farmaceutici (AKANTO)

(Case T-182/17)

(2017/C 161/46)

Language in which the application was lodged: English

Parties

Applicant: Novartis AG (Basel, Suisse) (represented by: L. Junquera Lara, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Chiesi Farmaceutici SpA (Parma, Italy)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Applicant

Trade mark at issue: EU word mark ‘AKANTO’ — Application for registration No 13 289 781

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the First Board of Appeal of EUIPO of 9 January 2017 in Case R 531/2016-1

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | declare that Article 8(1)(b) of Regulation No 207/2009 does not preclude the sign at issue (European trade mark No 13 289 781) in respect of the goods in class 5 described in the application for registration; |

|  |  |
| --- | --- |
| — | order EUIPO to pay the costs. |

Plea in law

|  |  |
| --- | --- |
| — | Infringement of Article 8(1)(b) of Regulation No 207/2009. |

---

[Top](#document1)